Navigation Links
Afinitor (Breast Cancer) - Analysis and Forecasts to 2020
Date:10/20/2011

Adjuvant, First Line and Second Line 23

6.3.2 Cytotoxic Chemotherapy 25

6.3.3 Management of Patients with HER-2 Positive Patients 27

7 Afinitor 29

7.1 Introduction 29

7.2 Mechanism of Action 29

7.3 Clinical Studies 29

7.3.1 Phase I/II trial to Determine the Safety and Efficacy of everolimus (E) plus trastuzumab (T) in Patients with T-resistant Metastatic Breast Cancer 29

7.3.2 Everolimus in Combination with trastuzumab and paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer (BOLERO-1) 30

7.3.3 Everolimus in Combination with exemestane in the Treatment of Postmenopausal Women with ER Positive Locally Advanced or Metastatic Breast Cancer who are Refractory to letrozole or anastrozole (BOLERO-2) 30

7.3.4 Daily everolimus in Combination with trastuzumab and vinorelbine in HER2 Positive women with Locally Advanced or Metastatic Breast Cancer (BOLERO-3) 30

7.4 Approval Status of Afinitor 30

7.5 Factors Affecting Sales of Afinitor 30

7.5.1 Absence of Competition from Neratinib in Japan 30

7.5.2 Patent Expiry of Aromasin before Launch of Afinitor for Breast Cancer 30

7.5.3 High Cost of Afinitor 31

7.6 Drug Risk Benefit Score 31

7.6.1 Efficacy 31

7.6.2 Safety 31

7.6.3 Compliance 31

7.6.4 Dosing Convenience 32

7.7 Intensity of Competition 32

7.8 Sales Forecasts 32

7.8.1 Target Patient Pool of Afinitor 32

7.8.2 Dosing 33

7.8.3 Market Penetration 33

7.8.4 Annual Cost of Therapy 34

7.8.5 Sales Projections of Afinitor 34

8 Appendix 44

8.1 Market Definitions 44

8.2 Abbreviations 44

8.3 Research Methodology 44

8.3.1 Coverage 44

8.3.2 Secondary Research 45

8.3.3 Forecasting 45

8.3.4 Number of Patients Approved to take the Drug 45

8.3.5 Net Penetration of Drug 46

8.3.6 Net Annual Dosing 47'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
2. Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
3. FDA Approves Novartis Drug Afinitor to Treat Pancreatic Neuroendocrine Tumors
4. Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET
5. Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
6. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
7. Study in NEJM Shows Novartis Drug Afinitor® Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
8. FDA Approves New Indication for Afinitor
9. VIDEO from thenewsmarket.com and Novartis: Novartis drug Afinitor® Approved by FDA as First Medication for Children and Adults With a Benign Brain Tumor Associated With Tuberous Sclerosis
10. Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
11. Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... /PRNewswire-iReach/ -- Full Service CRO WCCT Global ... President of Business Development. Peter has been in the ... of different business development positions with some of the ... related to business development/sales management and marketing.  The experience ... him a key and strategic asset to WCCT Global ...
(Date:7/25/2014)... , July 25, 2014  The Chemistry, ... Tobago Ministry of Health approved the introduction of ... increases the cure rate from Hepatitis C, and ... genotype 1 virus. Telaprevir is available in ... INCIVO®. Photo - http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpg   ...
(Date:7/25/2014)... , July 25, 2014  Solanbridge Group Inc ... acquired the majority interest in Buzznbrewz.com and the Letter ... replaced with a fully executed Purchase Agreement. ... stated "We are proud to have Mr. David ... decades of experience in the private sector and developed ...
Breaking Medicine Technology:Contract Research Organization WCCT Global Welcomes Peter Nieto as Vice President of Business Development 2The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2
... , , CHARLOTTESVILLE, Virginia, December ... the 2009 Top Innovator Presentation Award,in Healthcare, at the ... Dedham, MA. The award, which recognizes cutting edge private ... who competed with,over 50 other privately held companies that ...
... , ... CVS/pharmacy and MinuteClinic health care centers located in select ... and Washington, D.C. While in some locations priority restrictions ... allowing all patients to be eligible to receive the shot ...
Cached Medicine Technology:Biovista Inc. Named Top Innovator in Life Sciences 2CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 2CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 3CVS/pharmacy and MinuteClinic Providing H1N1 Vaccines in 20 States and Washington, D.C. 4
(Date:7/28/2014)... (PRWEB) July 28, 2014 Termed by ... drug abuse causes more fatal overdoses than heroin and ... year. (1) Those who are particularly vulnerable to succumbing ... and up), with many in this age group taking ... this growing epidemic was reawakened in the White House ...
(Date:7/28/2014)... Freeonlinelifeinsuranceleads.com has released a new blog ... insurance quotes. , Comparing life insurance quotes can help ... costs. Finding affordable coverage is easier online by visiting ... agencies and displays them on a single web page. ... find cheaper coverage, but they can also learn more ...
(Date:7/28/2014)... HealthDay Reporter FRIDAY, July 25, 2014 (HealthDay News) ... blood donations from gay and bisexual men, according to a team ... Journal of the American Medical Association . Currently, a man ... in the United States -- a lifetime ban that has been ... adopted this policy at the dawn of the AIDS crisis. ...
(Date:7/28/2014)... By Dennis Thompson ... -- The U.S. Supreme Court,s ruling on contraception coverage -- ... to a legal quagmire that might allow companies to deny ... principles, some health care experts say. But other experts ... The justices ruled 5-4 last month that Hobby Lobby Stores ...
(Date:7/28/2014)... July 28, 2014 For those with dust ... cause of dust allergies—commonly settle in mattresses, bedding, and upholstered ... , Dust mites are microscopic insects that feed on the ... each day to keep a million dust mites fat and ... high power microscope, the decaying bodies and feces of dust ...
Breaking Medicine News(10 mins):Health News:Rx Drug Abuse Labeled Silent Killer: Claims Nearly 17,000 American Lives a Year; Novus Medical Detox Solution Involves Education and Governmental Support 2Health News:Rx Drug Abuse Labeled Silent Killer: Claims Nearly 17,000 American Lives a Year; Novus Medical Detox Solution Involves Education and Governmental Support 3Health News:Rx Drug Abuse Labeled Silent Killer: Claims Nearly 17,000 American Lives a Year; Novus Medical Detox Solution Involves Education and Governmental Support 4Health News:Comparing Life Insurance Quotes Online Offers 3 Important Advantages! 2Health News:Lift U.S. Ban on Blood Donations by Gay Men, Experts Say 2Health News:Lift U.S. Ban on Blood Donations by Gay Men, Experts Say 3Health News:The 'Hobby Lobby Ruling' and What It Means for U.S. Health Care 2Health News:The 'Hobby Lobby Ruling' and What It Means for U.S. Health Care 3Health News:The 'Hobby Lobby Ruling' and What It Means for U.S. Health Care 4Health News:The 'Hobby Lobby Ruling' and What It Means for U.S. Health Care 5Health News:AllergyEasy® Announces No-shots Immunotherapy to Mitigate Dust Allergies 2Health News:AllergyEasy® Announces No-shots Immunotherapy to Mitigate Dust Allergies 3
... Present Clinical Data at, ... Upcoming Scientific Meeting -,LAVAL, QC, May ... ) today announced the publication of Extended Release Trazodone in Major ... issue of the journal Psychiatry (Edgemont) (Volume 6, Number 5) ( ...
... German . , When cells cannot carry out ... is disease. Nanobiotechnology researchers are looking for ways to allow ... absent from the cell. This requires transport systems that can ... controlled fashion at the right moment. The transporter must be ...
... Pharmaceutical Research and Manufacturers of America (PhRMA) unveiled a ... for diabetes. The report shows that America,s pharmaceutical research ... diabetes medicines. The medicines listed in the report are ... approval by the U.S. Food and Drug Administration.The report ...
... delivery and glucose sensing leadership INDIANAPOLIS and MINNEAPOLIS, May ... diabetes management -Eli Lilly and Company (NYSE: ... ) - today announced a strategic marketing collaboration to ... manage their blood sugar using insulin therapy.Working collaboratively with ...
... Leading Veterinary Care Digital Imaging and Data Management ... 19 Eklin Medical Systems, a leading provider ... and Communications Systems) and practice management software (VIA(R)) ... Juan Thorn as the company,s West Coast ultrasound ...
... ,sings, could improve our understanding of conditions such as ... at Cardiff University have discovered. , Research by ... Centre (CUBRIC) has discovered that a person,s brain produces ... a person looks at a visual pattern. , ...
Cached Medicine News:Health News:Results of phase III study on Labopharm's novel antidepressant published in Psychiatry (Edgemont) Journal 2Health News:Results of phase III study on Labopharm's novel antidepressant published in Psychiatry (Edgemont) Journal 3Health News:Results of phase III study on Labopharm's novel antidepressant published in Psychiatry (Edgemont) Journal 4Health News:Capsules encapsulated 2Health News:New Report Released in North Carolina Shows Record Number of Medicines in Development to Treat Diabetes 2Health News:New Report Released in North Carolina Shows Record Number of Medicines in Development to Treat Diabetes 3Health News:New Report Released in North Carolina Shows Record Number of Medicines in Development to Treat Diabetes 4Health News:Lilly and Medtronic Form Alliance to Provide Solutions for Diabetes Management 2Health News:Lilly and Medtronic Form Alliance to Provide Solutions for Diabetes Management 3Health News:Lilly and Medtronic Form Alliance to Provide Solutions for Diabetes Management 4Health News:Eklin Medical Systems Appoints Juan Thorn as West Coast Ultrasound Sales Representative 2Health News:'Singing brains' offers epilepsy and schizophrenia clues 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: